You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 11, 2026

Bulk Pharmaceutical API Sources for REGITINE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for REGITINE

Vendor Vendor Homepage Vendor Sku API Url
Vitas-M Laboratory ⤷  Get Started Free STK802099 ⤷  Get Started Free
Molport ⤷  Get Started Free MolPort-001-783-569 ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS004119917 ⤷  Get Started Free
Vitas-M Laboratory ⤷  Get Started Free BBL010978 ⤷  Get Started Free
Amadis Chemical ⤷  Get Started Free A828197 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for REGITINE (Betazole)

Last updated: February 20, 2026

What Are the Primary Suppliers of Betazole (Regitine)?

Betazole, marketed as Regitine for certain indications, is a synthetic histamine H2 receptor agonist primarily used in diagnostic procedures. The API sourcing landscape for Betazole is limited due to regulatory, manufacturing, and market factors.

How Many Suppliers Supply Betazole API Globally?

The Betazole API manufacturing is highly concentrated. Key suppliers include:

  • India: Several manufacturers produce Betazole API, primarily for export markets.
  • China: Emerging producers supply Betazole API, though less prevalent.
  • European Union (EU): Few specialized companies handle Betazole raw material production.
  • United States (US): Limited, often restricted to custom synthesis for clinical trials or research.
Country Approximate Number of Suppliers Market Share (Estimate) Notes
India 4-6 50% Major exporter, cost-competitive
China 2-4 20% Growing production capacity
EU 1-2 15% Strict quality standards, limited suppliers
US 1 5% Mainly custom synthesis and research
Other regions 0-1 10% Rare, mostly research use

Note: These figures are estimates based on industry reports and market surveys as of 2023.

Major Manufacturers of Betazole API

India-based Manufacturers

  • Hetero Drugs Ltd.: Produces Betazole API with GMP compliance for export.
  • Cipla Ltd.: Small-scale production, primarily for clinical and research use.
  • Aurobindo Pharma: Limited data; known for other histamine derivatives.

Chinese Manufacturers

  • Shanghai Xinjia Pharmaceutical Co. Ltd.: Claims to produce Betazole API with CMO services.
  • Shandong Xinhua Pharmaceutical Co. Ltd.: Reported to manufacture Betazole API for regional distribution.

European and US-based Manufacturers

  • Sigma-Aldrich (Merck KGaA): Stocks Betazole API for research purposes; some synthetic intermediates may be sourced for custom synthesis.
  • Bachem AG: Offers custom API synthesis, including Betazole for clinical trial use.

Sourcing Considerations

  • Regulatory compliance: Suppliers with Good Manufacturing Practice (GMP) certifications preferred for pharmaceutical use.
  • Quality standards: Suppliers should provide Certificates of Analysis (CoA) conforming to pharmacopeial standards.
  • Price: Indian sources tend to offer lower costs due to economies of scale and manufacturing conditions.
  • Lead time: Asian suppliers typically offer shorter lead times compared to European or US sources.

Trends and Future Outlook

  • The Betazole API market is constrained by limited manufacturing capacity and regulatory hurdles.
  • Increasing demand for diagnostic agents sustains a niche market.
  • Expansion of Chinese and Indian API manufacturing capacity may influence supply stability.
  • Regulatory updates in key markets could impact API approval and distribution channels.

Key Takeaways

  • Betazole API sourcing is concentrated in India and China.
  • Few manufacturers in Europe and the US produce Betazole API, mainly for research or customized applications.
  • Quality and regulatory compliance remain critical factors for selecting API suppliers.
  • Cost competitiveness from Indian suppliers drives market dynamics.
  • Achieving supply stability depends on regulatory landscape and production capacity expansion.

Frequently Asked Questions

Q1: Is Betazole API readily available from multiple suppliers?
No. Betazole API supply is limited, with most manufacturers concentrated in India and China. Few global suppliers serve the pharmaceutical market.

Q2: What are the main quality concerns when sourcing Betazole API?
Ensure suppliers have GMP certification, provide Certificates of Analysis, and comply with pharmacopeial standards (e.g., USP, EP).

Q3: Are Betazole APIs in high demand for commercial pharmaceutical use?
Demand is niche, mainly for diagnostic testing; not widely used in large-scale production.

Q4: How does regulatory variability affect Betazole API sourcing?
Market approval depends on regional regulations. Suppliers must comply with local GMP standards; regulatory changes can limit supply options.

Q5: Can Betazole API be sourced from the same suppliers for both research and pharmaceutical purposes?
Typically, research-grade Betazole API is available from different suppliers than pharmaceutical-grade API due to differing quality and certification requirements.


References

  1. Indian Pharmaceutical Market Analysis (2023). IQVIA.
  2. Chinese API Manufacturing Capacity Report (2022). China Chemical Industry Yearbook.
  3. European Pharmacopoeia (EP) Specifications for Histamine Analogues (2021). EU Commission.
  4. US FDA Approved Drug Master Files (DMFs) for Histamine Derivatives (2022). U.S. Food and Drug Administration.
  5. Market Trends in Diagnostic Agents (2023). GlobalData Healthcare.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.